Welcome to our dedicated page for Kymera Therapeutics news (Ticker: KYMR), a resource for investors and traders seeking the latest updates and insights on Kymera Therapeutics stock.
Kymera Therapeutics develops targeted protein degradation medicines for immunological diseases as a clinical-stage biopharmaceutical company. News about KYMR commonly centers on oral small molecule degrader programs, including KT-621, a STAT6 degrader for Type 2 inflammatory diseases such as atopic dermatitis and asthma, and KT-579, an IRF5 degrader tied to inflammatory bowel disease biology.
Company updates also cover preclinical and clinical data presentations, FDA regulatory designations, collaboration activity involving degrader candidates such as KT-200, and periodic operating and financial results. Additional announcements include investor conference participation and shareholder voting matters.
Kymera Therapeutics, Inc. announced its first quarter 2024 financial results, reporting $745 million in cash. The company is advancing various clinical-stage programs with data expected in 2025. Business updates include expanding the pipeline with a focus on immunology, unveiling oral degrader programs for STAT6 and TYK2, and ongoing Phase 1 studies for MDM2 and STAT3 inhibitors. Kymera remains well-capitalized and has extended its cash runway into 2027.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.